Quell Therapeutics is a London, UK and Boston, MA-based company developing engineered T‑regulatory (Treg) cell therapies to address serious medical conditions driven by the immune system. Its platform is designed to enable the design, engineering and scalable manufacture of therapeutic Treg products, and includes proprietary Phenotype‑Lock technology to stabilise an immunosuppressive phenotype, CAR modules for tissue targeting, and additional modules to enhance disease‑specific efficacy and safety. The lead candidate, QEL-001, is an antigen‑specific multi‑modular CAR‑Treg being developed to induce operational tolerance following liver transplantation and is entering the LIBERATE Phase 1/2 clinical trial. Quell is also advancing programs in neuroinflammatory and autoimmune diseases and is developing both autologous and allogeneic CAR‑Treg platforms. The company intends to use recently raised capital to fund LIBERATE, advance its pipeline across transplantation, neuroinflammation and autoimmunity, and accelerate platform development. Quell raised $156M in a Series B to support these efforts. Quell Therapeutics is developing engineered T regulatory (Treg) cell therapies that leverage Tregs' immune-suppressive capacity. The company aims to advance therapies for indications including solid organ transplant rejection and autoimmune and inflammatory diseases. Quell was founded by Syncona in partnership with six leading experts in Treg biology, cell engineering, transplantation and autoimmune disease. The company plans to use the Series A proceeds to initiate development of its first program and to build out operations and its management team. Syncona's team will work closely with Quell as it advances its programs and expands the company.

Total raised

$201M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2021